48. ~~A method for performing a colonoscopy; an enteroscopy or endoscopy; a capsule endoscopy; a viewing of the intestinal or colonic mucosa; a surgical or an investigative, therapeutic or ameliorative, prophylactic or radiological procedure involving the intestine or colon; comprising:~~

~~administering~~ Use of a composition of claim 1 or an article of manufacture of claim 38, or a pharmaceutical composition, preparation or formulation, or food, feed, supplement or additive, of claim 39, in the manufacture of a medicament, for a colonoscopy; an enteroscopy or endoscopy; a capsule endoscopy; a viewing of the intestinal or colonic mucosa; a surgical or an investigative, therapeutic or ameliorative, prophylactic or radiological procedure involving the intestine or colon, into an individual in need thereof~~; or the method of (a)~~, wherein the individual is a human or an animal.

49. ~~A method for the amelioration, treatment and/or prevention of constipation or bloating, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, comprising administering~~ Use of a composition of claim 1, or an article of manufacture of claim 38, or a pharmaceutical composition, preparation or formulation, or food, feed, supplement or additive, of claim 39, in the manufacture of a medicament for the amelioration, treatment and/or prevention of constipation or bloating, abdominal pain, particularly non-specific abdominal pain, or diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea~~to an individual in need thereof~~.

50. The ~~method~~ use of claim 49, wherein the constipation or bloating is due to at least one of: travel; change in daily routine; lack of exercise; immobility caused by injury, illness, or aging; dehydration; irritable bowel syndrome; pregnancy; diabetes; hypothyroidism; hypercalcemia; cancer of the colon or rectum; uterine prolapse; vaginal vault prolapse; rectal prolapse; scarring from surgery; injury of the colon or rectum; Parkinson's disease; multiple sclerosis; stroke; hemorrhoids or anal fissures; delaying bowel movements; anxiety; depression; eating disorders; and/or obsessive-compulsive disorder, coeliac disease, muscular dystrophy, myotonic dystrophy, non-specific abdominal pain, or a neurological condition or any cause of constipation.

51. ~~A method for the amelioration or treatment of a bowel disease, comprising administering~~ Use of a composition of claim 1 , or an article of manufacture of claim 38, or a pharmaceutical composition, preparation or formulation, or food, feed, supplement or additive, of claim 39, in the manufacture of a medicament for the amelioration or treatment of a bowel disease~~to an individual in need thereof~~,

wherein the bowel disease or condition having a bowel dysfunction component, comprises: an inflammatory bowel disease (IBD), Crohn's disease, hepatic encephalopathy, enteritis, colitis, irritable bowel syndrome (IBS), fibromyalgia (FM), chronic fatigue syndrome (CFS), depression, attention deficit/hyperactivity disorder (ADHD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), travelers' diarrhea, small intestinal bacterial overgrowth, chronic pancreatitis, or a pancreatic insufficiency.

58. The package or kit of claim 52, wherein the contents of the second container comprises or consists of capsules (or pills, tablets, geltabs, and the like) comprising the following formulation: Magnesium sulphate, Sodium sulphate, Potassium gluconate, Sodium chloride and Erythritol.

59. The package or kit of claim 58, comprising the following amounts:

Second container

Magnesium sulphate	4.05g
Sodium sulphate	8.68g
Potassium gluconate	1.74g
Sodium chloride	1.74g
Erythritol	1.74g,

60. The package or kit of claim 58 wherein the first container comprises 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 or more capsules.

61. A package or kit comprising a formulation contained in a container (e.g., a bottle or blister pack or equivalent) wherein a patient is administered or instructed to take the contents of the container.

62. The package or kit of claim 61, wherein the contents of the container comprises or consists of capsules (or pills, tablets, geltabs, and the like) comprising the following formulation: Bisoxatin, Magnesium sulphate, Sodium sulphate, Potassium gluconate, Sodium chloride, and Erythritol.

63. The package or kit of claim 62, comprising the following amounts:

Bisoxatin	240mg
Magnesium sulphate	7gm
Sodium sulphate	3gm
Potassium gluconate	3gm
Sodium chloride	4gm
Erythritol	2gm

64. The package or kit of claim 63, wherein the container comprises between about 10 to 40 or more capsules.

65. The package or kit of claim 64 wherein the first container comprises 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 or more capsules.

66. ~~A method for administering a combination of (at least two) different formulations that are designed to be taken in sequence as part of a treatment or a colonoscopy preparation~~

~~regimen, comprising administering~~ Use of the first and second container in the package or kit of any of claims 52-60 in the manufacture of a medicament for a treatment or a colonoscopy preparation regimen, wherein ~~the contents of the first container, then several hours later or the next day~~ the contents of the second container are to be administered several hours later or the next day after the contents of the first container have been administered., ~~wherein the first and second container are in the package or kit of any of claims 52-60,~~

67. The ~~method~~ use of claim 66, wherein the first container comprises capsules, pills, tablets, geltabs, or the like, and the second container comprises capsules, pills, tablets, geltabs, or the like, and the first container comprises about 16 capsules to be taken or administered first, and the second container comprises about 22 capsules to be taken later or the next day.

~~6368~~. The ~~method~~ use of claim ~~6266~~, wherein the first container comprises capsules, pills, tablets, geltabs, or the like, and the second container comprises capsules, pills, tablets, geltabs, or the like, and the first container comprises about 32 capsules to be taken or administered first, and the second container comprises about 6 capsules to be taken later, or the next day.

69. Use of the pharmaceutical composition, preparation or formulation of claim 39, in the manufacture of a purgative, or in the manufacture of a medicament for orthostatic lavage; a colonoscopy; an enteroscopy or endoscopy; a capsule endoscopy; a viewing of the intestinal or colonic mucosa; or a surgical or an investigative, therapeutic or ameliorative, prophylactic or radiological procedure involving the intestine or colon.

70. Use of the pharmaceutical composition, preparation or formulation of claim 39, in the manufacture of a medicament for the amelioration, treatment and/or prevention of constipation or bloating, abdominal pain, particularly non-specific abdominal pain, or diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea.

71. Use of the pharmaceutical composition, preparation or formulation of claim 39, in the manufacture of a medicament for the amelioration or treatment of a bowel disease, wherein optionally the bowel disease or condition having a bowel dysfunction component, comprises: an inflammatory bowel disease (IBD), Crohn's disease, hepatic encephalopathy, enteritis, colitis, irritable bowel syndrome (IBS), fibromyalgia (FM), chronic fatigue syndrome (CFS), depression, attention deficit/hyperactivity disorder (ADHD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), travelers' diarrhea, small intestinal bacterial overgrowth, chronic pancreatitis, or a pancreatic insufficiency.